Biomedical Jobmarket
DOD Alert
Edit DOD
Forgotten Password?
"Persistence of Diabetes" - Why Has Research into Type 1 Diabetes not Made Significant Advances?
Diabetes OD > Reversal/Prevention of Diabetes > T1DM > Journal Article

(Journal Article): "Persistence of Diabetes" - Why Has Research into Type 1 Diabetes not Made Significant Advances?
Sia C, Weinem M (Vaccine Center, National Health Research Institutes, 35 Keyan Road, Zhunan Township, Miaoli County, Taiwan, )
IN: Rev Diabet Stud 2006; 3(4):156-160

Fulltext:    HTML  PDF




  1. World Health Organization. Diabetes mellitus: report of a WHO study group. Technical Report Series no. 727, WHO, Geneva. [DOD]
  2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004. 27(5):1047-1053. [DOD]
  3. Banting FG, Best CH. Pancreatic extracts. J Lab Clin Med 1922. 7:251-266.
  4. Ryan EA, Lakey JR, Paty BW, Imes S, Korbutt GS, Kneteman NM, Bigam D, Rajotte RV, Shapiro AM. Successful islet transplantation: continued insulin reserve provides long-term glycemic control. Diabetes 2002. 51:2148-2157. [DOD]
  5. Hanninen A, Jalkanen S, Salmi M, Toikkanen S, Nikolakaros G, Simell O. Macrophages, T cell receptor usage, and endothelial cell activation in the pancreas at the onset of insulin-dependent diabetes mellitus. J Clin Invest 1992. 90:1901-1910.
  6. Imagawa A, Hanafusa T, Tamura S, Moriwaki M, Itoh N, Yamamoto K, Iwahashi H, Yamagata K, Waguri M, Nanmo T, et al. Pancreatic biopsy as a procedure for detecting in situ autoimmune phenomenon in type 1 diabetes. Diabetes 2001. 50:1269-1273.
  7. Fuchtenbusch M, Rabl W, Grassl B, Bachmann W, Standl E, Ziegler AG. Delay of type 1 diabetes in high risk, first degree relatives by parental antigen administration: The Schwabing Insulin Prophylaxis Pilot Trial. Diabetologia 1998. 41:536-541.
  8. Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. Diabetes Prevention Trial. N Engl J Med 2002. 346:1685-1691.
  9. Alleva DG, Crowe PD, Jin L, Kwok WW, Ling N, Gottschalk M, Conlon PJ, Gottlieb PA, Putnam AL, Gaur A. A disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulin. J Clin Invest 2001. 107(2):173-180.
  10. Agardh CD, Cilio CM, Lethagen A, Lynch K, Leslie RD, Palmer M, Harris RA, Robertson JA, Lernmark A. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 2005. 19(4):238-246.
  11. Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 2001. 358(9295):1749-1753.
  12. Schloot NC, Meierhoff G, Lengyel C, Vandorfi G, Takacs J, Panczel P, Barkai L, Madacsy L, Oroszlan T, Kovacs P, Suto G, Battelino T, Hosszufalusi N, Jermendy G. Effect of heat shock protein peptide DiaPep277 on ss-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials. Diabetes Metab Res Rev 2007. In press.
  13. Huurman VA, Decochez K, Mathieu C, Cohen IR, Roep BO. Therapy with the hsp60 peptide DiaPep277(trade mark) in C-peptide positive type 1 diabetes patients. Diabetes Metab Res Rev 2007. In press.
  14. Herold KC, Bluestone JA, Montag AG, Parihar A, Wiegner A, Gress RE, Hirsch R. Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes 1992. 41:385-391.
  15. Chatenoud L, Bach JF. Questioning four preconceived ideas on immunotherapy of clinical type 1 diabetes: lessons from recent CD3 antibody trials. Rev Diabet Stud 2005. 2(3):116-120. [DOD]
  16. Bresson D, von Herrath M. Limitations in immunotherapy with CD3 antibodies: comment on the article by Drs. Chatenoud and Bach. Rev Diabet Stud 2005. 2(4):187-189. [DOD]
  17. Rapoport MJ, Mor A, Vardi P, Ramot Y, Winker R, Hindi A, Bistritzer T. Decreased secretion of Th2 cytokines precedes up-regulated and delayed secretion of Th1 cytokines in activated peripheral blood mononuclear cells from patients with insulin-dependent diabetes mellitus. J Autoimmun 1998. 11(6):635-642.
  18. Ko KS, Lee M, Koh JJ, Kim SW. Combined administration of plasmids encoding IL-4 and IL-10 prevents the development of autoimmune diabetes in nonobese diabetic mice. Mol Ther 2001. 4(4):313-316.
  19. Goudy K, Song S, Wasserfall C, Zhang YC, Kapturczak M, Muir A, Powers M, Scott-Jorgensen M, Campbell-Thompson M, Crawford JM, Ellis TM, Flotte TR, Atkinson MA. Adeno-associated virus vector-mediated IL-10 gene delivery prevents type 1 diabetes in NOD mice. Proc Natl Acad Sci USA 2001. 98:13913-13918.
  20. Lee M, Koh JJ, Han SO, Ko KS. Prevention of autoimmune insulitis by delivery of interleukin-4 plasmid using a soluble and biodegradable polymeric carrier. Pharm Res 2002. 19(3):246-249.
  21. Feili-Hariri M, Falkner DH, Gambotto A, Papworth GD, Watkins SC, Robbins PD, Morel PA. Dendritic cells transduced to express interleukin-4 prevent diabetes in nonobese diabetic mice with advanced insulitis. Hum Gene Ther 2003. 14(1):13-23.
  22. Poulton LD, Smyth MJ, Hawke CG, Silveira P, Shepherd D, Naidenko OV, Godfrey DI, Baxter AG. Cytometric and functional analyses of NK and NKT cell deficiencies in NOD mice. Int Immunol 2001. 13(7): 887-896.
  23. Hammond KJ, Poulton LD, Palmisano LJ, Silveira PA, Godfrey DI, Baxter AG. Alpha/beta-T cell receptor (TCR)+CD4-CD8- (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J Exp Med 1998. 187(7): 1047-1056.
  24. Hong S, Wilson MT, Serizawa I, Wu L, Singh N, Naidenko OV, Miura T, Haba T, Scherer DC, Wei J, Kronenberg M, Koezuka Y, Van Kaer L. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune. Nat Med 2001. 7(9):1052-1056.
  25. Sharif S, Arreaza GA, Zucker P, Mi QS, Sondhi J, Naidenko OV, Kronenberg M, Koezuka Y, Delovitch TL, Gombert JM, et al. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents. the onset and recurrence of autoimmune type 1 diabetes. Nat Med 2001. 7:1057-1062.
  26. Kukreja A, Cost G, Marker J, Zhang C, Sun Z, Lin-Su K, Ten S, Sanz M, Exley M, Wilson B, Porcelli S, Maclaren N. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest 2002. 109(1):131-140.
  27. Lee PT, Putnam A, Benlagha K, Teyton L, Gottlieb PA, Bendelac A. Testing the NKT cell hypothesis of human IDDM pathogenesis. J Clin Invest 2002. 110(6):793-800.
  28. Osman Y, Kawamura T, Naito T, Takeda K, Van Kaer L, Okumura K, Abo T. Activation of hepatic NKT cells and subsequent liver injury following administration of alpha-galactosylceramide. Eur J Immunol 2000. 30(7):1919-1928.
  29. Major AS, Singh RR, Joyce S, Van Kaer L. The role of invariant natural killer T cells in lupus and atherogenesis. Immunol Res 2006. 34(1):49-66.
  30. Maclaren N, Atkinson M. Is insulin-dependent diabetes mellitus environmentally induced. N Engl J Med 1992. 327:348-349.
  31. Davies JL, Kawaguchi Y, Bennett ST, Copeman JB, Cordell HJ, Pritchard LE, Reed PW, Gough SC, Jenkins SC, Palmer SM, et al. A genome-wide search for human type 1 diabetes susceptibility genes. Nature 2002. 371(8):130-136.
  32. Sospedra M, Ferrer-Francesch X, Dominguez O, Juan M, Foz-Sala M, Pujol-Borrell R. Transcription of broad range of self-antigens in human thymus suggests a role for central mechanisms in tolerance toward peripheral antigens. J Immunol 1998. 161:5918-5929.
  33. Pugliese A, Zeller M, Fernandez A Jr, Zalcberg LJ, Bartlett RJ, Ricordi C, Pietropaolo M, Eisenbarth GS, Bennett ST, Patel DD. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat Genet 1997. 15:293-297.
  34. Vafiadis P, Bennett ST, Todd JA, Nadeau J, Grabs R, Goodyer CG, Wickramasinghe S, Colle E, Polychronakos C. Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nat Genet 1997. 15:289-292.
  35. DeVoss J, Hou Y, Johannes K, Lu W, Liou GI, Rinn J, Chang H, Caspi R, Fong L, Anderson MS. Spontaneous autoimmunity prevented by thymic expression of a single self-antigen. J Exp Med 2006. 203(12):2727-2735.
  36. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999. 48(12):2270-2276.
  37. Li L, Yi Z, Seno M, Kojima I. Activin A and betacellulin: effect on regeneration of pancreatic beta-cells in neonatal streptozotocin-treated rats. Diabetes 2004. 53(3):608-615.
  38. Suzuki A, Nakauchi H, Taniguchi H. Prospective isolation of multipotent pancreatic progenitors using flow-cytometric cell sorting. Diabetes 2004. 53:2143-2152.

Respond on this Journal Article!
Hint: Your Response should directly apply to "Persistence of Diabetes" - Why Has Research into Type 1 Diabetes not Made Significant Advances?. Please check, if this context applies best to your contribution. Otherwise click HERE to change to the appropriate subject area. The actual subject area is T1DM.